Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published online as doi:10.1189/jlb.1004569 on May 20, 2005

Published online before print May 20, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1004569v1
78/2/555    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baratelli, F.
Right arrow Articles by Dubinett, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baratelli, F.
Right arrow Articles by Dubinett, S. M.
(Journal of Leukocyte Biology. 2005;78:555-564.)
© 2005 by Society for Leukocyte Biology

PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells

Felicita Baratelli, Kostyantyn Krysan, Nathalie Heuzé-Vourc’h, Li Zhu, Brian Escuadro, Sherven Sharma, Karen Reckamp, Mariam Dohadwala and Steven M. Dubinett1

UCLA Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center and the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Geffen School of Medicine at University of California Los Angeles; and Molecular Gene Medicine Laboratory, Veteran’s Affairs Greater Los Angeles Healthcare System, California

1 Correspondence: Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine, UCLA Geffen School of Medicine, 37-131 CHS, 10833 Le Conte Ave., Room 37-131 CHS, Los Angeles, CA 90095. E-mail: sdubinett{at}mednet.ucla.edu

Control of apoptosis is fundamental for dendritic cell (DC) homeostasis. Numerous factors maintain DC viability throughout their lifespan, including inhibitor of apoptosis proteins. Among them, survivin is overexpressed in many human malignancies, but its physiological function in normal cells has not been fully delineated. Prostaglandin E2 (PGE2), also overproduced in several malignancies, has shown to induce proapoptotic and antiapoptotic effects in different cell types, including immune cells. In DC, PGE2 predominantly affects maturation and modulates immune functions. Here, we show that exposure of monocyte-derived DC to PGE2 (105 M) for 72 h significantly increased DC survivin mRNA and protein expression. In contrast, DC, matured with lipopolysaccharide or tumor necrosis factor {alpha}, did not reveal survivin induction in response to PGE2. Following exposure to apoptotic stimuli, DC treated with PGE2 exhibited an overall increased viability compared with control DC, and this effect was correlated inversely with caspase-3 activation. Moreover, PGE2-treated, survivin-deficient DC demonstrated reduced viability in response to apoptotic stimuli. Further analysis indicated that PGE2 induced DC survivin expression in an E prostanoid (EP)2/EP4 receptor and phosphatidylinositol-3 kinase-dependent manner. These findings suggest that PGE2-dependent regulation of survivin is important in modulating apoptosis resistance in human DC.

Key Words: lipid mediators • immune cells • antiapoptotic proteins




This article has been cited by other articles:


Home page
Stem CellsHome page
J.-Y. Liou, D. P. Ellent, S. Lee, J. Goldsby, B.-S. Ko, N. Matijevic, J.-C. Huang, and K. K. Wu
Cyclooxygenase-2-Derived Prostaglandin E2 Protects Mouse Embryonic Stem Cells from Apoptosis
Stem Cells, May 1, 2007; 25(5): 1096 - 1103.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Thurnher
Lipids in dendritic cell biology: messengers, effectors, and antigens
J. Leukoc. Biol., January 1, 2007; 81(1): 154 - 160.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. T. Mao, M. C. Fishbein, B. Adams, M. D. Roth, L. Goodglick, L. Hong, M. Burdick, E. R. M. Strieter, C. Holmes, D. P. Tashkin, et al.
Celecoxib Decreases Ki-67 Proliferative Index in Active Smokers
Clin. Cancer Res., January 1, 2006; 12(1): 314 - 320.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society for Leukocyte Biology.